Viking Therapeutics, Inc.

Listed Company

VKTXCIK 0001607678NasdaqLarge AcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

Net Income

$-359.64M

Total Assets

$715.73M

Equity

$639.06M

Shares Out

115.89M

Op. Cash Flow

$-278.69M

Business

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel first-in-class or best-in-class therapies for metabolic and endocrine disorders. It develops therapeutic candidates including VK2735, a dual GLP‑1/GIP agonist in oral and subcutaneous formulations for obesity; VK2809 and VK0214, orally available selective TRß agonists targeting NASH/MASH and X‑ALD respectively; VK5211, an oral selective androgen receptor modulator for post‑hip‑fracture recovery; and a preclinical DACRA obesity program. The company organizes operations around clinical development programs, preclinical research and partnering/licensing activities. It conducts multinational clinical trials and pursues regulatory approvals and third‑party manufacturing and commercialization in the U.S., Europe and other global markets.

Summary from filing dated 2025-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenues	0	0	0	0	0
Research and development	345	102	64	54	45
General and administrative	48	49	37	16	11
Total operating expenses	393	151	101	70	56
Loss from operations	−393	−151	−101	−70	−56
Amortization of financing costs	−56,000	−94,000	−88,000	−59,000	−18,000
Interest income, net	34	41	15	2	703,000
Realized gain on investments, net	55,000	112,000	0	−42,000	—
Total other income, net	34	41	15	1	692,000
Net loss	−360	−110	−86	−69	−55
Unrealized gain (loss) on securities	1	−173,000	742,000	−295,000	−495,000
Foreign currency translation gain (loss)	47,000	−226,000	−29,000	−258,000	0
Comprehensive loss	−358	−110	−85	−69	−55
Basic net loss per common share	−3.19	−1.01	−0.91	−0.9	−0.71
Weighted-average shares used to compute basic net loss per share	113	109	94	77	77
Diluted net loss per common share	−3.19	−1.01	−0.91	−0.9	−0.71
Weighted-average shares used to compute diluted net loss per share	113	109	94	77	77

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	166	27	56	37	26
Short-term investments available for sale	540	876	307	119	176
Prepaid clinical trial and preclinical study costs	8	3	3	8	8
Prepaid expenses and other current assets	2	1	3	3	619,000
Total current assets	716	907	367	167	211
Right-of-use assets	85,000	1	1	1	25,000
Deferred financing costs	0	56,000	106,000	38,000	76,000
Deposits	46,000	46,000	33,000	33,000	33,000
Total assets	716	908	368	169	211
Accounts payable	53	10	8	9	1
Other accrued liabilities	23	17	11	13	7
Lease liability, current	137,000	489,000	324,000	304,000	29,000
Total current liabilities	77	27	19	22	9
Lease liability, net of current portion	0	630,000	936,000	1	—
Total long-term liabilities	0	630,000	936,000	1	—
Total liabilities	77	28	20	23	9
Commitments and contingencies (Note 10)	—	—	—	—	—
Preferred stock, $0.00001 par value: 10,000,000 shares authorized at December 31, 2025 and December 31, 2024; no shares issued and outstanding at December 31, 2025 and December 31, 2024	—	—	—	—	—
Common stock, $0.00001 par value: 300,000,000 shares authorized at December 31, 2025 and December 31, 2024; 114,793,067 shares issued and outstanding at December 31, 2025 and 111,573,519 shares issued and outstanding at December 31, 2024	1,000	1,000	1,000	1,000	1,000
Treasury stock at cost, no shares at December 31, 2025 and December 31, 2024	0	0	−7	−7	—
Additional paid-in capital	1,486	1,369	734	445	426
Accumulated deficit	−848	−488	−378	−292	−223
Accumulated other comprehensive loss	378,000	−788,000	−389,000	−1	−549,000
Total stockholders equity	639	880	348	145	202
Total liabilities and stockholders equity	716	908	368	169	211

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−360	−110	−86	−69	−55
(Accretion) amortization of investment premiums	−9	−17	−8	1	4
Stock-based compensation	41	30	17	9	6
Amortization of right-of-use assets	431,000	346,000	292,000	291,000	296,000
Interest expense related to operating lease liability	10,000	38,000	43,000	41,000	11,000
Prepaid expenses and other current assets	−5	446,000	6	−3	−711,000
Accrued interest, net of interest receivable on maturity of investments	5	1	321,000	614,000	1
Accounts payable	43	2	−1	7	−3
Accrued expenses	6	6	−2	6	−506,000
Lease liability	−505,000	−402,000	−347,000	−189,000	−342,000
Net cash used in operating activities	−279	−88	−73	−48	−48
Purchases of investments	−418	−1,113	−478	−121	−168
Proceeds from sales and maturities of investments	759	560	299	176	206
Net cash (used in) provided by investing activities	341	−553	−179	55	38
Public offering, net of offering costs	0	597	270	−22,000	−46,000
Value of shares withheld related to employee tax withholding	0	−42	−7	−2	−707,000
Proceeds from warrant and option exercises and stock issuances under employee stock purchase plan	2	11	7	848,000	8
ATM offering, net of fees	74	47	2	12	—
Net cash provided by financing activities	76	612	271	4	7
Net (decrease) increase in cash and cash equivalents	139	−29	19	11	−3
Effect of exchange rate changes on cash	−8,000	−148,000	−30,000	−258,000	—
Unpaid deferred public offering and other financing costs	50,000	50,000	50,000	31,000	50,000
Right-of-use asset obtained in exchange for lease obligation	0	223,000	0	2	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro